Asfotase alfa - Alexion Pharmaceuticals

Drug Profile

Asfotase alfa - Alexion Pharmaceuticals

Alternative Names: ALXN1215; Asfotase alpha; ENB-0040; Strensiq

Latest Information Update: 27 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Enobia Pharma
  • Developer Alexion Pharmaceuticals
  • Class Recombinant fusion proteins
  • Mechanism of Action Alkaline phosphatase stimulants; Esterase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypophosphatasia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hypophosphatasia
  • Preclinical Neurofibromatoses

Most Recent Events

  • 17 Mar 2018 Final efficacy and adverse events data from a long term extension trial in Hypophosphatasia (paediatric onset hypophosphatasia) presented at the 100th Annual Meeting of the Endocrine Society (ENDO-2018)
  • 17 Mar 2018 Pharmacodynamics and adverse events data from a phase IIa trial in Hypophosphatasia (paediatric-onset hyperphosphataemia) presented at the the 100th Annual Meeting of the Endocrine Society (ENDO-2018)
  • 05 Jul 2017 NICE recommends asfotase alfa for the treatment of paediatric-onset hypophosphatasia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top